{
    "clinical_study": {
        "@rank": "92516", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A nutrient formulation without the active ingredient"
            }, 
            {
                "arm_group_label": "Nutrient formulation", 
                "arm_group_type": "Experimental", 
                "description": "Nutrient formulations with variable amounts of active ingredients."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether food ingredient(s) affect glycemic and\n      insulinemic responses."
        }, 
        "brief_title": "PEP-1324: Glycemic Response Testing", 
        "condition": "Glycemic Response", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is 18-75 years of age\n\n          -  Subject is male or non-pregnant females, 18-75 years of age, inclusive\n\n          -  Subject has a body mass index (BMI) \u2265 20.0 and < 35 kg/m\u00b2 at screening (visit 1).\n\n          -  Subject has to be non-smoker.\n\n          -  Subject is willing to maintain habitual diet, physical activity pattern, and body\n             weight throughout the trial.\n\n          -  Subject is willing to maintain current dietary supplement use throughout the trial.\n             On test days, subject agrees not to take any dietary supplements until dismissal from\n             the GI labs. Failure to comply will result in a rescheduled test visit.\n\n          -  Subject has normal fasting serum glucose (<7.0mmol/L capillary corresponding to whole\n             blood glucose <6.3mmol/L).\n\n          -  Subject is willing to abstain from alcohol consumption and avoid vigorous physical\n             activity for 24 h prior to all test visits.\n\n          -  Subject has no health conditions that would prevent him from fulfilling the study\n             requirements as judged by the Investigator on the basis of medical history.\n\n          -  Subject understands the study procedures and signs forms providing informed consent\n             to participate in the study and authorization for release of relevant protected\n             health information to the study investigator.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037854", 
            "org_study_id": "PEP-1324"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "Nutrient formulation"
            ], 
            "intervention_name": "Nutrient formulation", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "contact": {
                "email": "JCampbell@gilabs.com", 
                "last_name": "Janice Campbell"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5C 2N8"
                }, 
                "name": "GI Labs"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "JCampbell@gilabs.com", 
            "last_name": "Janice Campbell"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: WIRB"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incremental area under the blood glucose response cruve", 
            "safety_issue": "No", 
            "time_frame": "0-2 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037854"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "peak blood glucose", 
                "safety_issue": "No", 
                "time_frame": "0-2 hours"
            }, 
            {
                "measure": "peak insulin", 
                "safety_issue": "No", 
                "time_frame": "0-2 hours"
            }
        ], 
        "source": "PepsiCo Global R&D", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PepsiCo Global R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}